H.C. Wainwright Reiterates Buy Rating on Structure Therapeutics (GPCR)

September 9, 2026 7:26 AM

H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating and $70.00 price target on Structure Therapeutics (NASDAQ: GPCR).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found